Literature DB >> 27607591

Therapeutic vaccines and immunological intervention in HIV infection: a paradigm change.

Giuseppe Pantaleo1, Yves Levy.   

Abstract

PURPOSE OF REVIEW: The purpose is to review current knowledge of immunological interventions in HIV infection and discuss strategies for the establishment of functional cure and/or HIV eradication. RECENT
FINDINGS: Therapeutic vaccines and cytokines have been historically the immunological interventions developed with the objective to enhance the HIV-specific cell-mediated immune responses and to suppress virus replication. Both these interventions have shown only partial antiviral effects. The recent identification and generation of human broad neutralizing antibodies provides potent immunological intervention associated with effective suppression of virus replication in the absence of antiretroviral therapy. Furthermore, the identification that the major HIV cell reservoir containing replication competent and infectious virus is composed by programed cell death protein 1 (PD-1) positive memory CD4 T cells offers the opportunity to target directly the HIV cell reservoir with anti-PD-1 antibodies. Anti-PD-1 antibody therapy may be also critical to prevent exhaustion of CD8 T cells.
SUMMARY: The availability of a diverse armamentarium of immunological intervention offers the opportunity to investigate the efficacy of the combined use of different immunological interventions in inducing prolonged virus suppression in the absence of antiretroviral therapy and functional cure HIV or HIV eradication.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27607591     DOI: 10.1097/COH.0000000000000324

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  21 in total

1.  HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal.

Authors:  Guoxin Wu; Michael Swanson; Aarthi Talla; Donald Graham; Julie Strizki; Daniel Gorman; Richard Jo Barnard; Wade Blair; Ole S Søgaard; Martin Tolstrup; Lars Østergaard; Thomas A Rasmussen; Rafick-Pierre Sekaly; Nancie M Archin; David M Margolis; Daria J Hazuda; Bonnie J Howell
Journal:  JCI Insight       Date:  2017-08-17

Review 2.  Regulatory T cells (Tregs): A major immune checkpoint to consider in combinatorial therapeutic HIV-1 vaccines.

Authors:  Audrey Hubert; Nabila Seddiki
Journal:  Hum Vaccin Immunother       Date:  2018-02-23       Impact factor: 3.452

Review 3.  On the Road to a HIV Cure: Moving Beyond Berlin and London.

Authors:  Nikolaus Jilg; Jonathan Z Li
Journal:  Infect Dis Clin North Am       Date:  2019-09       Impact factor: 5.982

4.  TLR3 agonist and CD40-targeting vaccination induces immune responses and reduces HIV-1 reservoirs.

Authors:  Liang Cheng; Qi Wang; Guangming Li; Riddhima Banga; Jianping Ma; Haisheng Yu; Fumihiko Yasui; Zheng Zhang; Giuseppe Pantaleo; Matthieu Perreau; Sandra Zurawski; Gerard Zurawski; Yves Levy; Lishan Su
Journal:  J Clin Invest       Date:  2018-08-27       Impact factor: 14.808

5.  Negative modulation of suppressive HIV-specific regulatory T cells by IL-2 adjuvanted therapeutic vaccine.

Authors:  Vedran Brezar; Lylia Hani; Mathieu Surenaud; Audrey Hubert; Christine Lacabaratz; Jean-Daniel Lelièvre; Yves Levy; Nabila Seddiki
Journal:  PLoS Pathog       Date:  2017-07-14       Impact factor: 6.823

Review 6.  Advancements in Developing Strategies for Sterilizing and Functional HIV Cures.

Authors:  Wei Xu; Haoyang Li; Qian Wang; Chen Hua; Hanzhen Zhang; Weihua Li; Shibo Jiang; Lu Lu
Journal:  Biomed Res Int       Date:  2017-04-26       Impact factor: 3.411

7.  Phenotype, Polyfunctionality, and Antiviral Activity of in vitro Stimulated CD8+ T-Cells From HIV+ Subjects Who Initiated cART at Different Time-Points After Acute Infection.

Authors:  Jimena Salido; María Julia Ruiz; César Trifone; María Inés Figueroa; María Paula Caruso; María Magdalena Gherardi; Omar Sued; Horacio Salomón; Natalia Laufer; Yanina Ghiglione; Gabriela Turk
Journal:  Front Immunol       Date:  2018-10-23       Impact factor: 7.561

8.  HIV-1 T cell epitopes targeted to Rhesus macaque CD40 and DCIR: A comparative study of prototype dendritic cell targeting therapeutic vaccine candidates.

Authors:  Anne-Laure Flamar; Henri Bonnabau; Sandra Zurawski; Christine Lacabaratz; Monica Montes; Laura Richert; Aurelie Wiedemann; Lindsey Galmin; Deborah Weiss; Anthony Cristillo; Lauren Hudacik; Andres Salazar; Cécile Peltekian; Rodolphe Thiebaut; Gerard Zurawski; Yves Levy
Journal:  PLoS One       Date:  2018-11-30       Impact factor: 3.240

Review 9.  Harnessing CD8+ T Cells Under HIV Antiretroviral Therapy.

Authors:  Joanna A Warren; Genevieve Clutton; Nilu Goonetilleke
Journal:  Front Immunol       Date:  2019-02-26       Impact factor: 7.561

10.  Rationale for an Association Between PD1 Checkpoint Inhibition and Therapeutic Vaccination Against HIV.

Authors:  Gilberto Filaci; Daniela Fenoglio; Lucia Taramasso; Francesco Indiveri; Antonio Di Biagio
Journal:  Front Immunol       Date:  2018-10-23       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.